We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Protein-Bound Paclitaxel Promising as First-Line Treatment in Non-Small-Cell Lung Cancer.
- Abstract
The article highlights the results of multiple phase II studies with Abraxis BioScience Inc.'s paclitaxel albumin-bound particles for injectable suspension (Abraxane) as a first-line treatment for late-stage non-small-cell lung cancer. It reports on the antitumor benefits of albumin-bound paclitaxel as first-line treatment over the solvent-based taxane treatment. The data were presented at the 2006 American Society of Clinical Oncology annual meeting in Atlanta, Georgia.
- Subjects
PACLITAXEL; CANCER treatment; DRUG efficacy; LUNG cancer; ABRAXIS BioScience Inc.
- Publication
Oncology (08909091), 2006, Vol 20, Issue 8, p936
- ISSN
0890-9091
- Publication type
Article